LOS ANGELES — In the nearly 11 years since researchers first rang alarm bells that women on hormone-replacement therapy faced an increased risk of breast cancer, some have suggested that taking estrogen and progestin to treat symptoms of menopause might not be so dangerous after all.
Though it was generally agreed that women who took the two hormones to curb their hot flashes and night sweats increased their chances of developing the disease, many studies suggested the cancers the women developed were less likely to be deadly.
A new analysis of data from the Women’s Health Initiative casts doubt on those findings. The study, published Friday by the Journal of the National Cancer Institute, concludes that the prognosis for cancers related to hormone-replacement therapy is just as dire as for other breast cancers. As a result, women who turn to the treatment are more likely to die of breast cancer than their nonhormone-taking peers.
“You could fill a basketball arena with the women who get the disease,” said Dr. Rowan Chlebowski, principal investigator for the Women’s Health Initiative and lead author of the new study. “It seems like you’d want to reach a higher threshold before you take it.”
- Win over USC puts UW’s coaching upgrade (Chris Petersen over Steve Sarkisian) on full display
- Lloyd McClendon will not return as Mariners' manager
- Expect traffic delays when Obama visits Seattle Friday afternoon
- Huskies upset USC 17-12 and beat Steve Sarkisian, their former coach
- Obama visits Seattle for fundraisers; traffic not as bad as expected
Most Read Stories
Nearly 70,000 postmenopausal women participated in randomized clinical trials as part of the Women’s Health Initiative. The study participants who took estrogen plus progestin had higher rates of breast-cancer diagnoses and of breast-cancer deaths.
At the same time, more than 90,000 additional women took part in a related observational study that tracked details about their health and hormone use over an average of 11 years. Along with many other observational studies, this one found that women who took hormones to treat menopause symptoms and got breast cancer were less likely to die from the illness than women who got breast cancer without taking hormones.
Chlebowski, an oncologist based at the Los Angeles Biomedical Research Institute in Torrance, suspected the discrepancy could have resulted from key differences between the women in the randomized trial and the women in the observational study.
So he and his team identified a subset of more than 41,000 women from the observational study who more closely matched the women who took part in the randomized trial.
The new results fell more closely in line with the findings from the original randomized trial: Survival after breast cancer was similar for both hormone users and nonusers, that is, tumors that arose in women who took hormones were no less deadly.
Dr. Patricia Ganz, director of cancer prevention and control research at UCLA’s Jonsson Comprehensive Cancer Center, applauded the study’s rigor.
“If you’re going to take these therapies, you need to know there’s an increased risk,” said Ganz, who was not involved in the study. “Make sure there’s a good indication. And don’t take them for a long period of time.”
The new findings apply only to women who take estrogen and progestin, a synthesized form of the natural hormone progesterone. Women who have had hysterectomies can take estrogen alone, a regimen that doesn’t seem to increase breast-cancer risk. But those who still have a uterus must take estrogen and progestin to avoid developing endometrial cancer.
When the Women’s Health Initiative was launched in 1993, about 40 percent of postmenopausal women were taking hormones. Many of them — and their doctors — believed they would get benefits, including improved bone, cardiovascular and cognitive health, Chlebowski said.
As research revealed that was not the case and that the treatment was associated with increased cancer risk, the number of users fell by half, about where it remains today.